“…Viable tumor volumes for liposomal doxorubicin plus RF ablation, EXPERIMENTAL STUDIES: Chemoradionuclide Therapy with 186 Re-labeled Liposomal Doxorubicin Soundararajan et al 186 Re-liposomal doxorubicin did not result in a signifi cant decrease in average tumor volume or viable tumor volume compared to that with 186 Re-liposomal doxorubicin alone, four of six rats showed a decreasing tumor volume at 6 weeks. Possible reasons why we did not see complete tumor control as achieved by Horkan et al ( 24 ) with a combination of radiation therapy and RF ablation are as follows: (a) The tumor diameter in our study was twice that reported by Horkan et al (2.05 cm 6 0.24 vs 1.0 cm, respectively); (b) 186 Re radiation dose rate is not constant owing to clearance and decay and, hence, could allow for repair and repopulation of tumor cells; (c) the width of the remaining pepercentage injected dose of FDG could be used to measure therapeutic effi cacy in addition to changes in tumor volume in a preclinical model.…”